{{Rsnum
|rsid=11638815
|Gene=AP3B2
|Chromosome=15
|position=82683530
|Orientation=plus
|GMAF=0.2002
|Gene_s=AP3B2,LOC283692
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 50.8 | 41.5 | 7.7
| HCB | 66.7 | 31.1 | 2.2
| JPT | 61.4 | 29.5 | 9.1
| YRI | 100.0 | 0.0 | 0.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 66.7 | 31.1 | 2.2
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PMID Auto GWAS
  |PMID=23118302
  |Trait=Lipoprotein-associated phospholipase A2 activity change in response to statin therapy
  |Title=Genome-wide association study evaluating lipoprotein-associated phospholipase A2 mass and activity at baseline and after rosuvastatin therapy.
  |RiskAllele=C
  |Pval=1E-6
  |OR=4.10
  |ORtxt=[2.14-6.06] nmol/min/ml increase
  }}

{{on chip | HumanOmni1Quad}}